On Nov. 19, 2025, Novartis, a leading global innovative medicines company, announced plans to expand its operations in North Carolina, creating a new flagship manufacturing hub with end-to-end manufacturing capabilities. The strategic investment is a major step to ensure all key Novartis medicines for US patients are manufactured in the US and delivered to patients across the country at scale.

This announcement is part of Novartis’ $23 billion investment in US-based infrastructure over the next five years, designed to increase manufacturing capacity and enable 100% of the company’s key medicines to be produced end-to-end in the US.

As part of this flagship hub in North Carolina, Novartis will: Expand the scope of its existing Durham facility with the added capability to support sterile filling of biologics into syringes and vials; Build a new site in Durham with the construction of two new facilities dedicated to manufacturing biologics and sterile packaging; and Build a new site in Morrisville with one facility for the production of solid dosage tablets and capsules, including packaging.

Currently, Novartis produces innovative, life-changing gene therapies in Durham. Together, the new and existing facilities will create a single hub, expanding capabilities to produce medicines across the company’s main therapeutic areas: oncology, immunology, neuroscience, and cardiovascular, renal and metabolic. The proximity of the facilities will allow teams and production processes to work in tandem – from manufacturing active ingredients to final packaging – and create efficiencies in its manufacturing.

Anticipated to open in 2027-2028, the flagship manufacturing hub, encompassing more than 700,000 square feet between the existing campus and new facilities, is expected to create 700 new jobs at Novartis and more than 3,000 indirect jobs across the supply chain by the end of 2030.